Intravenous and Subcutaneous Immunoglobulin Therapy
Authors:
Thon Vojtěch
Authors place of work:
Ústav klinické imunologie a alergologie, Lékařská fakulta Masarykovy univerzity a FN u sv. Anny v Brně
Published in the journal:
Epidemiol. Mikrobiol. Imunol. 62, 2013, č. 2, s. 64-73
Summary
Patients with agammaglobulinaemia and hypogammaglobulinaemia require immunoglobulin G (IgG) replacement therapy to prevent serious infections. Since the 1950s, therapy with human immune globulin products has been the standard of treatment. Currently, the most common routes of administration of IgG replacement therapy are intravenous (IVIG) or subcutaneous (SCIG). The home therapy may improve the quality of life in patients who require lifelong IgG replacement. The anti-IgA antibody test identifies the patients with the risk of anaphylactoid reactions in IVIG replacement. The SCIG delivery may be used in patients with anti-IgA antibodies and previous systemic reactions to IVIG.
Keywords:
IVIG – SCIG – immunodeficiency – immunoglobulin – anti-IgA antibodies
Zdroje
1. Abrahamsen, T. G., Sandersen, H., Bustnes, A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics, 1996, 98, p. 1127–1131.
2. Al-Herz, W., Bousfiha, A., Casanova, J. L., Chapel, H., Conley, M. E., Cunningham-Rundles, C., Etzioni, A., Fischer, A., . L., Geha, R. S., Hammarström, L., Nonoyama, S., Notarangelo, L. D., Ochs, H. D., Puck, J. M., Roifman, C. M., Seger, R., Tang, M. L. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol., 2011, 2, p. 1–26.
3. Ballow, M. Immunoglobulin therapy: replacement and immunomodulation. In Clinical Immunology, Principles and Practice. Elsevier, 2008, Chapter 85, p. 1265–1280.
4. Berger, M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol. Allergy Clin. North Am., 2008, 28, p. 413–437.
5. Berger, M., Cupps, T. R., Fauci, A. S. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann. Intern. Med., 1980, 93, p. 55–56.
6. Bruton, O. C. Agammaglobulinemia. Pediatrics, 1952, 9, p. 722–728.
7. CENTERS FOR DISEASE CONTROL (CDC) Renal insuficiency and failure associated with immune globulin intravenous therapy – United States 1985–1998. MMWR Morb Mortal Wkly Rep., 1999, 48, p. 518–521.
8. CENTERS FOR DISEASE CONTROL (CDC) Outbreak of hepatitis C associated with intravenous immunoglobulin administration: United States Oct 1993–June 1994. MMWR Morb Mortal Wkly Rep., 1994, 43, p. 505–509.
9. Cohn, E. J. The history of plasma fractionation. In Merler, E. Advances inmilitary medicine, vol. 1. Boston: Little, Brown and Company, 1948. p. 364–443.
10. Eibl, M. M., Wolf, H. M. Immunglobulintherapie. In Pädiatrische Allergologie und Immunologie, Urban und Fischer, 1999, Kap. 38, p. 401–409.
11. Gardulf, A., Hammarström, L., Smith, C. I. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet, 1991, 338, p. 162–166.
12. Gelfand, E. W. Differences between IGIV products: impact on clinical outcome. Int. Immunopharmacol., 2006, 6, p. 592–599.
13. Good, R. A., Varco, R. L. A clinical and experimental study of agammaglobulinemia. Lancet, 1955, 75, p. 245–271.
14. Hoernes, M., Seger, R., Reichenbach, J. Modern management of primary B-cell immunodeficiencies. Pediatr Allergy Immunol., 2011, 22, p. 758–769.
15. Hansen, S., Gustafson, R., Smith, C. I., Gardulf, A. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin. Immunol., 2002, 104, p. 237–241.
16. Horn, J., Thon, V., Bartonkova, D., Salzer, U., Warnatz, K., Schlesier, M., Peter, H. H., Grimbacher, B. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin. Immunol., 2007, 122, p. 156–162.
17. Chapel, H., Lucas, M., Lee, M., Bjorkander, J., Webster, D., Grimbacher, B., Fieschi, C., Thon, V., Abedi, M. R., Hammarstrom, L. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood, 2008, 112, p. 277–286.
18. Christie, J. M., Healey, C. J., Watson, J., Wong, V. S., Duddridge, M., Snowden, N., Rosenberg, W. M., Fleming, K. A., Chapel, H., Chapman, R. W. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2-year follow-up. Clin. Exp. Immunol., 1997, 110, p. 4–8.
19. Litzman, J., Stikarovska, D., Pikulova, Z., Pavlik, T., Pesak, S., Thon, V., Kuklinek, P., Lokaj, J. Change in referral diagnoses and diagnostic delay in hypogammaglobulinaemic patients during 28 years in a single referral centre. Int. Arch. Allergy Immunol., 2010, 153, p. 95–101.
20. Maarschalk-Ellerbroek, L. J., Hoepelman, I. M., Ellerbroek, P. M. Immunoglobulin treatment in primary antibody deficiency. Int. J. Antimicrob. Agents, 2011, 37, p. 396–404.
21. Misbah, S., Sturzenegger, M. H., Borte, M., Shapiro, R. S., Wasserman, R. L., Berger, M., Ochs, H. D. Subcutaneous immunoglobulin: opportunities and outlook. Clin. Exp. Immunol., 2009, 158, p. 51–59.
22. Orange, J. S., Hossny, E. M., Weiler, C. R., Ballow, M., Berger, M., Bonilla, F. A., Buckley, R., Chinen, J., El-Gamal, Y., Mazer, B. D., Nelson, R. P., Jr., Patel, D. D., Secord, E., Sorensen, R. U., Wasserman, R. L., Cunningham-Rundles,C.; Primary Immunodeficiency Committee Of The American Academy Of Allergy, Asthma And Immunology Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol., 2006, 117, p. S525–553.
23. Rachid, R., Castells, M., Cunningham-Rundles, C., Bonilla, F. A. Association of anti-IgA antibodies with adverse reactions to γ-globulin infusion. J. Allergy Clin. Immunol., 2011, 128, p. 228–230.
24. Skoda-Smith, S., Torgerson, T. R., Ochs, H. D. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther. Clin. Risk Manag., 2010, 6, p. 1–10.
25. Skvaril, F., Gardi, A. Differences among available immunoglobulin preparations for intravenous use. Pediatr. Infect. Dis. J., 1988, 7, p. S43–48.
26. Stiehm, R. E., Chapel, H. Conventional Therapy of Primary Immunodeficiency Diseases. In Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. Oxford University Press, 2007, Chapter 46, p. 655–668.
27. Thomas, M. J., Brennan, V. M., Chapel, H. H. Rapid subcutaneous immunoglobulin infusions in children. Lancet, 1993, 342, p. 1432–1433.
28. Thon, V. Importance of screening IgG anti-IgA antibodies in hypogammaglobulinemic subjects to prevent anaphylactoid reactions. Klinická imunológia a alergológia, 2010, 20, p. 26–27.
29. Thon, V., Vlkova, M., Chovancova, Z., Litzman, J., Lokaj, J. Flow Based Enumeration of Plasmablasts in Peripheral Blood After Vaccination as a Novel Diagnostic Marker for Assessing Antibody Responses in Patients with Hypogammaglobulinaemia. In Clinical Flow Cytometry – Emerging Applications, Ingrid Schmid (Ed.), InTech, 2012, Chapter 7, p. 125–142. ISBN: 978-953-51-0575-6. Dostupné na www: http://www.intechopen.com/books/clinical-flow-cytometry-emerging-applications/
30. Torgerson, T. R. Overview of routes of IgG administration. J. Clin. Immunol., 2013, 33, Suppl 2, p. S87–89.
31. Welles, C. C., Tambra, S., Lafayette. R. A. Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion. Am. J. Kidney Dis., 2010, 55, p. 148–151.
Štítky
Hygiene and epidemiology Medical virology Clinical microbiologyČlánok vyšiel v časopise
Epidemiology, Microbiology, Immunology
2013 Číslo 2
Najčítanejšie v tomto čísle
- Intravenous and Subcutaneous Immunoglobulin Therapy
- Antibiotická rezistence u netyfových sérovarů Salmonella spp. v České republice
- A Novel Typing Method and Scheme for Streptococcus pneumoniae
- Salmonellosis Outbreaks in the Czech Republic in 2012